As a surrogate biomarker, TIDE scores can provide insight into whether a NSCLC patient will respond to immune checkpoint blockades, including anti-PD1 and anti-CTLA4, if therapy is initiated. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.